Who owns Arcutis Biotherapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of ARQT from SEC Form 13F filings across 272 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 272 institutions disclosed 131.4M shares of Arcutis Biotherapeutics, Inc. worth $3.45B — about 100.7% of shares outstanding; the largest disclosed holder is MONTANOVA CAPITAL, LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
272
13F holders
$3.45B
value, 2026 filers
100.7%
of shares outstanding (131.4M sh)
44
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of ARQT's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | MONTANOVA CAPITAL, LLC | 12.4M | $326.1M | 6.0% | 9.5% | +0.9% |
| 2 | BlackRock, Inc. | 10.5M | $276.5M | 0.0% | 8.1% | +14.6% |
| 3 | Frazier Life Sciences Management, L.P. | 9.9M | $258.9M | 5.6% | 7.6% | 0.0% |
| 4 | Rubric Capital Management LP | 8.3M | $216.9M | 2.0% | 6.3% | 0.0% |
| 5 | Polar Capital Holdings Plc | 6.6M | $173.2M | 0.4% | 5.1% | +16.6% |
| 6 | STATE STREET CORP | 5.8M | $152.7M | 0.0% | 4.5% | -7.5% |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 5.0M | $130.8M | 0.0% | 3.8% | +2.4% |
| 8 | MORGAN STANLEY | 4.5M | $116.7M | 0.0% | 3.4% | +5.5% |
| 9 | JENNISON ASSOCIATES LLC | 4.2M | $110.6M | 0.1% | 3.2% | -15.3% |
| 10 | D. E. Shaw & Co., Inc. | 3.9M | $103.6M | 0.0% | 3% | +58.2% |
| 11 | UBS Group AG | 3.3M | $87.4M | 0.0% | 2.6% | +0.1% |
| 12 | BANK OF AMERICA CORP /DE/ | 3.0M | $78.3M | 0.0% | 2.3% | +34.5% |
| 13 | GEODE CAPITAL MANAGEMENT, LLC | 3.0M | $78.2M | 0.0% | 2.3% | -2.1% |
| 14 | VANGUARD PORTFOLIO MANAGEMENT LLC | 2.4M | $63.7M | 0.0% | 1.9% | +24.3% |
| 15 | ORBIMED ADVISORS LLCNEW | 2.0M | $53.5M | 1.0% | 1.6% | new |
| 16 | FRANKLIN RESOURCES INC | 1.9M | $50.6M | 0.0% | 1.5% | -16.0% |
| 17 | AMERICAN CENTURY COMPANIES INC | 1.9M | $50.5M | 0.0% | 1.5% | +31.6% |
| 18 | GOLDMAN SACHS GROUP INC | 1.7M | $43.7M | 0.0% | 1.3% | +4.1% |
| 19 | Jupiter Topco LLCNEW | 1.4M | $37.0M | 0.0% | 1.1% | new |
| 20 | OBERWEIS ASSET MANAGEMENT INC/ | 1.4M | $36.0M | 0.7% | 1.1% | +0.5% |
| 21 | GILDER GAGNON HOWE & CO LLC | 1.3M | $34.4M | 0.4% | 1% | -69.5% |
| 22 | GW&K Investment Management, LLC | 1.3M | $33.8M | 0.3% | 1% | +30.3% |
| 23 | Pivotal bioVenture Partners Investment Advisor LLC | 1.3M | $33.2M | 10.8% | 1% | -6.7% |
| 24 | BAMCO INC /NY/ | 1.3M | $32.9M | 0.0% | 1% | +16.9% |
| 25 | CITADEL ADVISORS LLC | 1.2M | $30.4M | 0.0% | 0.9% | +7333.1% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.